# Intranasal Resveratrol Plus Carboxymethyl-β-Glucan: A Promising Option in Clinical Practice

## TL;DR

Intranasal resveratrol combined with CMBG shows promise for treating upper airway diseases due to its effectiveness and safety in clinical studies.

## Contribution

The development and clinical validation of an intranasal formulation combining resveratrol and CMBG for upper airway diseases.

## Key findings

- The intranasal formulation of resveratrol and CMBG demonstrated stability and solubility in preclinical studies.
- Clinical studies showed the formulation is effective and safe for respiratory infections, allergic rhinitis, and nasal surgery.
- The combination offers a promising alternative for managing upper airway diseases.

## Abstract

Resveratrol is a polyphenol with numerous beneficial properties, acting as a phytoalexin. Plants produce resveratrol in response to various types of stress, such as infections and external damage. Resveratrol is a natural medicine thanks to its antimicrobial, antioxidant, anti-inflammatory, immunomodulatory, and antiallergic properties. However, resveratrol has poor oral bioavailability. To overcome this drawback, a topical nasal formulation has been developed, characterized by the fixed combination of carboxymethyl-β-glucan (CMBG) with trans-resveratrol. This innovative molecule has been the subject of in-depth preclinical studies to demonstrate its stability and solubility. Subsequently, several controlled clinical studies have shown that this formulation is effective and safe in patients with respiratory infections, allergic rhinitis, and nasal surgery. Therefore, taken together, these findings suggest that intranasal resveratrol–CMBG might be a promising option for the management of upper airway diseases.